# Michael Farrell

> Michael “Mick” Farrell is Resmed’s chairman and chief executive, based in San Diego. An engineer educated at UNSW and MIT, he joined Resmed in 2000, became CEO in 2013 and chairman in 2023. He also chairs AdvaMed and serves as lead independent director at Zimmer Biomet.

- **Role:** Chairman and Chief Executive Officer at Resmed
- **Organizations:** Resmed, AdvaMed, Zimmer Biomet, Father Joe’s Villages, Boston College Engineering Advisory Board, UC San Diego Rady School of Management Dean’s Advisory Council
- **From:** Seattle, United States
- **Nationality:** American and Australian
- **Education:** Bachelor of Engineering in chemical engineering, first-class honours, University of New South Wales, Master of Science in chemical engineering, Massachusetts Institute of Technology, Master of Business Administration, Leaders for Global Operations programme, MIT Sloan School of Management
- **Known for:** Advanced from joining Resmed in 2000 to CEO in 2013 and chairman in 2023., Led Resmed during its expansion into connected technology and software., Appointed lead independent director at Zimmer Biomet in 2025.

## Career timeline

- **1994** — Graduated from UNSW in chemical engineering with first-class honours.
- **Before 2000** — Worked at BHP, Dow, Genzyme and Arthur D. Little.
- **1998** — Completed graduate engineering and business studies at MIT.
- **2000** — Joined Resmed in September; held marketing and business development roles.
- **2007–2011** — Senior vice president of a global Resmed business unit.
- **2011–2013** — President of Resmed’s Americas region.
- **2013** — Became Resmed CEO and director on March 1.
- **2014** — Joined Zimmer Biomet’s board in December.
- **2015** — Joined the AdvaMed board.
- **2023** — Became Resmed chairman on January 25; Peter Farrell became chairman emeritus.
- **2025** — Became Zimmer Biomet lead independent director in January.
- **2026** — Began a two-year term as AdvaMed board chair in January.

## Achievements

- Advanced from joining Resmed in 2000 to CEO in 2013 and chairman in 2023.
- Led Resmed during its expansion into connected technology and software.
- Appointed lead independent director at Zimmer Biomet in 2025.
- Selected as AdvaMed chair for 2026–2027.
- Resmed reported approximately US$5.7 billion annual revenue for fiscal 2026, up 10%.

## Latest updates

- **2026-10** — Signed Resmed’s fiscal 2026 proxy shareholder letter as chairman and CEO, thanking a workforce of more than 11,300.
- **2026-08** — Resmed reported fiscal 2026 revenue of approximately US$5.7 billion, up 10%, and US$1 billion returned to shareholders.
- **2026-01** — Began his two-year term as AdvaMed board chair.
- **2025-01** — Became Zimmer Biomet lead independent director.

## Links

- Website: https://www.resmed.com/en-us/about-us/executive-team/
- LinkedIn: https://www.linkedin.com/in/michaelmickfarrell
- Twitter/X: https://x.com/ResMedMick

---

Profile page: https://yespress.io/michael-farrell
Published by YesPress — https://yespress.io
Last updated: 2026-10-21